Aldosterone receptor antagonists: Biology and novel therapeutic applications

Current Hypertension Reports

Volumn 7, Issue 3, 2005, Pages 206-211

  Magni, Paolo ^a   Motta, Marcella ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENOATE POTASSIUM; CANRENONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FUROSEMIDE; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ARTICLE; ATAXIA; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; DROWSINESS; DRUG ABSORPTION; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HEADACHE; HEART FAILURE; HEART INFARCTION; HIRSUTISM; HORMONE SYNTHESIS; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; IMPOTENCE; LETHARGY; LIBIDO DISORDER; MENSTRUAL IRREGULARITY; METABOLIC ACIDOSIS; NONHUMAN; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPEECH DISORDER;

EID: 21244432776     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-005-0012-5     Document Type: Article

References (45)

1. Jeunemaitre X, Kreft-Jais C, Chatellier G, et al.: Long-term experience of spironolactone in essential hypertension. Kidney Int Suppl 1988, 26:S14-S17.
2. Glorioso N, Tonolo G, Troffa C, et al.: Recognition of markers of response to potassium-canrenoate in essential hypertension. Steroids 1995, 60:105-109.
3. Campbell SE, Diaz-Arias AA, Weber KT: Fibrosis of the human heart and systemic organs in adrenal adenoma. Blood Press 1992, 1:149-156.
4. Young MJ, Funder JW: The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 1996, 271:E883-E888.
5. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990, 82:1730-1736.
6. Duprez DA, Bauwens FR, De Buyzere ML, et al.: Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 1993, 71:17A-20A.
7. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
8. Pitt B, Williams G, Remme W, et al.: The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001, 15:79-87.
9. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
10. Tan LB, Schlosshan D, Barker D: Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. Int J Cardiol 2004, 96:321-333.
11. Silvestre JS, Robert V, Heymes C, et al.: Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem 1998, 273:4883-4891.
12. Struthers AD: Evidence for myocardial synthesis of aldosterone producing myocardial fibrosis in man. Clin Sci (Lond) 2002, 102:387.
13. Hatakeyama H, Miyamori I, Fujita T, et al.: Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994, 269:24316-24320.
14. Arriza JL, Weinberger C, Cerelli G, et al.: Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268-275.
15. Lombes M, Farman N, Bonvalet JP, Zennaro MC: Identification and role of aldosterone receptors in the cardiovascular system. Ann Endocrinol (Paris) 2000, 61:41-46.
16. Kellendonk C, Gass P, Kretz O, et al.: Corticosteroid receptors in the brain: gene targeting studies. Brain Res Bull 2002, 57:73-83.
17. Christ M, Sippel K, Eisen C, Wehling M: Non-classical receptors for aldosterone in plasma membranes from pig kidneys. Mol Cell Endocrinol 1994, 99:R31-R34.
18. Kagawa CM, Cella JA, Van Arman CG: Action of new steroids in blocking effects of aldosterone and deoxycorticosterone on salt. Science 1957, 126:1015-1016.
19. Fanestil DD: Mechanism of action of aldosterone blockers. Semin Nephrol 1988, 8:249-263.
20. Armanini D, Karbowiak I, Goi A, et al.: In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol (Oxf) 1985, 23:341-347.
21. Dupont A: Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate. Lancet 1985, 2:731.
22. McMahon EG: Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 2001, 1:190-196.
23. de Gasparo M, Joss U, Ramjoue HP, et al.: Three new epoxyspirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987, 240:650-656.
24. de Gasparo M, Whitebread SE, Preiswerk G, et al.: Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989, 32:223-227.
25. Mantero F, Lucarelli G: Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol (Paris) 2000, 61:52-60.
26. Mantero F, Opocher G, Rocco S, et al.: Long-term treatment of mineralocorticoid excess syndromes. Steroids 1995, 60:81-86.
27. Staessen J, Lijnen P, Fagard R, et al.: Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981, 91:457-465.
28. McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056-1064.
29. Epstein M, Alexander J, Roniker B: Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA) in patient with mild to moderate hypertension. Hypertension 1999, 33:1075.
30. Danser AH, van Kats JP, Verdouw PD, Schalekamp MA: Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation 1997, 96:3795-3796.
31. Sica DA, Gehr TW, Yancy G: Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism. Congest Heart Fail 2003, 9:224-229.
32. Stier CT Jr, Chander PN, Rocha R: Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 2002, 10:97-107.
33. Mizuno Y, Yoshimura M, Yasue H, et al.: Aldosterone production is activated in failing ventricle in humans. Circulation 2001, 103:72-77.
34. Satoh M, Nakamura M, Saitoh H, et al.: Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond) 2002, 102:381-386.
35. Modena MG, Aveta P, Menozzi A, Rossi R: Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001, 141:41-46.
36. Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700-2706.
37. Weber KT, Brilla CG: Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991, 83:1849-1865.
38. Brilla CG, Matsubara LS, Weber KT: Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993, 71:12A-16A.
39. The Consensus Trial Study Group: Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med 1987, 316:1429-1435.
40. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991, 325:293-302.
41. Vantrimpont P, Rouleau JL, Ciampi A, et al.: Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998, 19:1552-1563.
42. Struthers AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996, 2:47-54.
43. Zannad F: Angiotensin-converting enzyme inhibitor and spironolactone combination therapy: new objectives in congestive heart failure treatment. Am J Cardiol 1993, 71:34A-39A.
44. Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871-3878.
45. Martinez DV, Rocha R, Matsumura M, et al.: Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension 2002, 39:614-618.